非诺贝特联合他汀类药物对冠心病合并高脂血症患者心功能及血脂指标的影响

doi:10.3969/j.issn.1671-7171.2023.11.034

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1233 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】To investigate the effect of fenofibrate combined with statins on cardiac function and serum lipid levels in patients with coronary heart disease and hyperlipidemia. 【Methods】A total of 120 patients with CHD and hyperlipidemia admitted to Genertec Universal Xi'an Beihuan Hospital from January 2019 to December 2021 were selected and divided into an observation group and a control group according to a random number table method,with 60 cases in each group. The control group was treated with rosuvastatin,while the observation group was treated with fenofibrate in addition to the control group. The therapeutic effects,changes in cardiac function indicators,serum inflammatory indicators,and serum lipid levels before and after treatment,as well as the incidence of adverse reactions,were compared between the two groups. 【Results】The total effective rate in the observation group was higher than that in the control group,and the difference was statistically significant(P<0.05). After treatment,the left ventricular end-diastolic diameter(LVEDD) in both groups was lower than that before treatment,while the left ventricular ejection fraction(LVEF) and cardiac output(CO) were higher than before treatment. The LVEDD in the observation group was lower than that in the control group,while the LVEF and CO were higher than those in the control group,and the differences were statistically significant(P<0.05). The levels of high-sensitivity C-reactive protein(hs-CRP),tumor necrosis factor-α(TNF-α),and interleukin-6(IL-6) in both groups were lower than those before treatment,and the observation group was lower than the control group,and the differences were statistically significant(P<0.05). The total cholesterol(TG),triglyceride(TC),and low-density lipoprotein(LDL-C) levels in both groups were lower than those before treatment,and the observation group was lower than the control group,and the differences were statistically significant(P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05). 【Conclusion】 The clinical application of fenofibrate combined with rosuvastatin in the treatment of coronary heart disease with hyperlipidemia is better than the use of rosuvastatin alone,which can effectively improve the patient's cardiac function,improve serum inflammatory factors,and improve serum lipid levels.

Key words： Coronary Disease/CO Hyperlipidemias/CO Fenofibrate/TU Hydroxymethylglutaryl-CoA Reductase Inhibitors Heart Function Tests

Received: 21 October 2022

PACS:

R541.4

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	HE Haixia
	WEI Wangfen

Cite this article:

HE Haixia,WEI Wangfen. Observation on the Effect of Fenofibrate Combined with Statins on the Cardiac Function and Blood Lipid Levels in Patients with Coronary Heart Disease and Hyperlipidemia[J]. JOURNAL OF CLINICAL RESEARCH, 2023, 40(11): 1730-1733.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2023.11.034 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2023/V40/I11/1730

[1] 郭丽娟,陆芳,扈晓霞,等. 不同剂量瑞舒伐他汀钙对老年冠心病合并高脂血症患者的有效性和安全性分析[J].中华老年医学杂志,2019,38(5):315-318.
[2] 金继斌,谢敬东. 辛伐他汀联合复方丹参滴丸治疗冠心病合并高脂血症64例临床疗效观察[J].智慧健康,2019,5(2):106-108.
[3] 刘云娣,张璐,孙伟鹏,等. 血脂康治疗冠心病合并高脂血症降脂效果的系统评价[J].中国中医基础医学杂志,2020,26(9):1305-1311.
[4] 袁爱梅,丁东新. 瑞舒伐他汀钙治疗高脂血症合并老年冠心病的临床研究[J].重庆医学,2020,49(S02):36-38.
[5] 李建军,石文娜. 依折麦布联合非诺贝特治疗混合型高脂血症及颈动脉斑块的临床疗效及安全性[J].中国老年学杂志,2020,40(4):720-722.
[6] 中华医学会心血管病学分会介入心脏病学组,中华医学会心血管病学分会动脉粥样硬化与冠心病学组,中国医师协会心血管内科医师分会血栓防治专业委员会,等.稳定性冠心病诊断与治疗指南[J].中华心血管病杂志,2018,46(9):680-694.
[7] 中国成人血脂异常防治指南修订联合委员会.中国成人血脂异常防治指南(2016年修订版)[J].中华心血管病杂志,2016,44(10):833-853.
[8] 刘艳宾,杨树涵,陈红伟,等. 老年冠心病患者脂肪细胞因子与冠状动脉病变严重程度的相关性[J].实用医学杂志,2019,35(11):1799-1804.
[9] 黄勇,李蔚华,尹虹,等. 冠心病患者幽门螺杆菌感染与斑块特征、脂代谢、炎症反应的相关性[J].中国动脉硬化杂志,2019,27(8):713-717.
[10] ZHANG L S,ZHANG J H,FENG R,et al. Efficacy and safety of berberine alone or combined with statins for the treatment of hyperlipidemia:a systematic review and meta-analysis of randomized controlled clinical trials[J].Am J Chin Med,2019,47(4):751-767.
[11] BISWAS K,TIWARI A,JADHAV P,et al. Rosuvastatin and fenofibrate combination in the treatment of mixed hyperlipidemia:a narrative review[J].Innov J,2021,4(3):867-877.
[12] 黄小燕,张为章,张照研,等. 非诺贝特对大鼠心肌缺血再灌注损伤的保护作用及其抑制NF-κB信号通路的作用机制[J].中国新药杂志,2020,29(10):1181-1186.
[13] PARK M S,YOUN J C,KIM E J,et al. Efficacy and safety of fenofibrate-statin combination therapy in patients with inadequately controlled triglyceride levels despite previous statin monotherapy:a multicenter,randomized,double-blind,Phase Ⅳ Study-science direct[J].Clin Ther,2021,43(17):1735-1747.

[1]	. [J]. JOURNAL OF CLINICAL RESEARCH, 2023, 40(8): 1259-1261.